Chief Executive Officer, Drug Farm
Appears in 1 story
Leading the company through late-stage development and the Series D raise
A few dozen families worldwide carry a gene mutation that slowly steals their sight and floods their bodies with inflammation. There is no approved drug that treats the cause. On July 13, 2026, Drug Farm said it raised $55 million to move its candidate for that disease, ROSAH syndrome, toward a Phase 3 trial.
Updated Yesterday
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
